Bristol Myers Squibb is partnering with Faro Health to use AI agents for clinical trial protocol design, drafting, validation and optimization. Faro’s technology structures narrative protocol elements—objectives, endpoints, and schedules—into digital assets that can be used across workflows with traceability. BMS said the collaboration reflects a shift away from document-based development processes, while Faro positioned its approach as a “system of record” for structured protocol design across BMS’s drug development organization. The tie-up matters for execution speed and compliance, particularly as sponsors look to reduce protocol iteration cycles and standardize internal review processes for regulators and research sites.